<DOC>
	<DOCNO>NCT02220907</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy co-administration Teneligliptin ( MP-513 ) Canagliflozin ( TA-7284 ) daily 52 week Japanese patient Type 2 diabetes mellitus receive treatment Teneligliptin inadequate glycemic control .</brief_summary>
	<brief_title>Long-Term Safety Study MT-2412 Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Men woman age ≥20 year old HbA1c ≥7.0 % &lt; 10.5 % FPG ≤ 270 mg/dL Patients dietary management take therapeutic exercise diabetes 12 week treatment period Patients type I diabetes , diabetes mellitus result pancreatic disorder , secondary diabetes Patients serious diabetic complication Patients hereditary glucosegalactose malabsorption primary renal glucosuria Patients Class III/IV heart failure symptom accord New York Heart Association ( NYHA ) functional classification Patients severe hepatic disorder severe renal disorder .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MT-2412</keyword>
	<keyword>MP-513</keyword>
	<keyword>TA-7284</keyword>
	<keyword>Teneligliptin</keyword>
	<keyword>Canagliflozin</keyword>
</DOC>